Tilray (NASDAQ:TLRY) Price Target Cut to $1.75 by Analysts at Roth Mkm

Tilray (NASDAQ:TLRY) had its price objective decreased by Roth Mkm from $2.00 to $1.75 in a report issued on Friday morning, Benzinga reports. Roth Mkm currently has a neutral rating on the stock.

Tilray Stock Performance

Shares of TLRY opened at $1.59 on Friday. The business’s fifty day moving average price is $1.75 and its 200 day moving average price is $1.85. Tilray has a 12-month low of $1.45 and a 12-month high of $2.97. The stock has a market capitalization of $1.34 billion, a PE ratio of -6.02 and a beta of 2.13. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.27 and a quick ratio of 1.42.

Tilray (NASDAQ:TLRY) last announced its quarterly earnings data on Thursday, October 10th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). Tilray had a negative return on equity of 2.01% and a negative net margin of 26.79%. The firm had revenue of $200.00 million for the quarter, compared to analysts’ expectations of $218.70 million. During the same period last year, the business posted ($0.10) earnings per share. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. Equities research analysts forecast that Tilray will post -0.16 EPS for the current year.

Institutional Investors Weigh In On Tilray

A number of hedge funds have recently added to or reduced their stakes in TLRY. Prospect Financial Services LLC bought a new stake in Tilray in the second quarter valued at $26,000. Wellington Wealth Strategies LLC. bought a new stake in Tilray in the fourth quarter valued at $29,000. Signature Estate & Investment Advisors LLC bought a new stake in Tilray in the second quarter valued at $29,000. Jeppson Wealth Management LLC bought a new stake in Tilray in the second quarter valued at $33,000. Finally, Vanguard Capital Wealth Advisors bought a new stake in Tilray in the second quarter valued at $34,000. 9.35% of the stock is currently owned by institutional investors.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.